LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Dasatinib | 1.11 | uM | LJP6 | 2 | I03 | 72 | hr | 1334 | 1474 | 3899 | 0.3780 | 0.0663 |
BT-20 | Dasatinib | 1.11 | uM | LJP6 | 3 | I03 | 72 | hr | 1334 | 1279 | 3921 | 0.3262 | -0.0270 |
BT-20 | Dasatinib | 1.11 | uM | LJP5 | 1 | D03 | 72 | hr | 1334 | 1376 | 3930 | 0.3501 | 0.0198 |
BT-20 | Dasatinib | 1.11 | uM | LJP5 | 2 | D03 | 72 | hr | 1334 | 1371 | 4051 | 0.3384 | 0.0169 |
BT-20 | Dasatinib | 1.11 | uM | LJP5 | 3 | D03 | 72 | hr | 1334 | 1658 | 4117 | 0.4027 | 0.1428 |
BT-20 | Dasatinib | 3.33 | uM | LJP6 | 1 | I02 | 72 | hr | 1334 | 906 | 3955 | 0.2290 | -0.2190 |
BT-20 | Dasatinib | 3.33 | uM | LJP6 | 2 | I02 | 72 | hr | 1334 | 915 | 3899 | 0.2347 | -0.2166 |
BT-20 | Dasatinib | 3.33 | uM | LJP6 | 3 | I02 | 72 | hr | 1334 | 1143 | 3921 | 0.2915 | -0.0949 |
BT-20 | Dasatinib | 3.33 | uM | LJP5 | 1 | D02 | 72 | hr | 1334 | 1205 | 3930 | 0.3066 | -0.0635 |
BT-20 | Dasatinib | 3.33 | uM | LJP5 | 2 | D02 | 72 | hr | 1334 | 1411 | 4051 | 0.3483 | 0.0353 |
BT-20 | Dasatinib | 3.33 | uM | LJP5 | 3 | D02 | 72 | hr | 1334 | 1309 | 4117 | 0.3179 | -0.0119 |
BT-20 | Dasatinib | 10 | uM | LJP6 | 1 | I01 | 72 | hr | 1334 | 569 | 3955 | 0.1438 | -0.4195 |
BT-20 | Dasatinib | 10 | uM | LJP6 | 2 | I01 | 72 | hr | 1334 | 937 | 3899 | 0.2403 | -0.2045 |
BT-20 | Dasatinib | 10 | uM | LJP6 | 3 | I01 | 72 | hr | 1334 | 839 | 3921 | 0.2140 | -0.2581 |
BT-20 | Dasatinib | 10 | uM | LJP5 | 1 | D01 | 72 | hr | 1334 | 1080 | 3930 | 0.2748 | -0.1270 |
BT-20 | Dasatinib | 10 | uM | LJP5 | 2 | D01 | 72 | hr | 1334 | 1017 | 4051 | 0.2510 | -0.1561 |
BT-20 | Dasatinib | 10 | uM | LJP5 | 3 | D01 | 72 | hr | 1334 | 1178 | 4117 | 0.2861 | -0.0740 |
BT-20 | Tozasertib | 0.04 | uM | LJP5 | 1 | B18 | 72 | hr | 1334 | 1673 | 3930 | 0.4256 | 0.1560 |
BT-20 | Tozasertib | 0.04 | uM | LJP5 | 2 | B18 | 72 | hr | 1334 | 1885 | 4051 | 0.4653 | 0.2405 |
BT-20 | Tozasertib | 0.04 | uM | LJP5 | 3 | B18 | 72 | hr | 1334 | 2277 | 4117 | 0.5530 | 0.3891 |
BT-20 | Tozasertib | 0.12 | uM | LJP5 | 1 | B17 | 72 | hr | 1334 | 1148 | 3930 | 0.2921 | -0.0922 |
BT-20 | Tozasertib | 0.12 | uM | LJP5 | 2 | B17 | 72 | hr | 1334 | 1196 | 4051 | 0.2952 | -0.0662 |
BT-20 | Tozasertib | 0.12 | uM | LJP5 | 3 | B17 | 72 | hr | 1334 | 1316 | 4117 | 0.3196 | -0.0086 |
BT-20 | Tozasertib | 0.37 | uM | LJP5 | 1 | B16 | 72 | hr | 1334 | 982 | 3930 | 0.2498 | -0.1787 |
BT-20 | Tozasertib | 0.37 | uM | LJP5 | 2 | B16 | 72 | hr | 1334 | 1108 | 4051 | 0.2735 | -0.1097 |